Quick View
Open Jobs (0)
About Us
As the global biopharmaceutical industry competes to address complex diseases like Alzheimer's, Parkinson's, and cancer, Creative Biolabs is making waves with its cutting-edge antibody discovery and development platform.
Leveraging artificial intelligence (AI) and a veteran team of doctoral scientists, the company is streamlining the path from target identification to therapeutic-potential recombinants—a critical advancement for an industry under pressure to deliver safer, faster, and more cost-effective treatment options.
Industry Revolve: Demand for Precision and Speed
The surge in neurodegenerative disorders and targeted cancer therapies has intensified the demand for highly specific antibodies, which, through traditional discovery methods, are time-consuming and labor-intensive to obtain, struggling to keep pace. "The old 'spray and pray' approach just doesn't cut it anymore," says a biotech analyst. "Companies that integrate AI and automation into their workflows are pulling ahead."
Creative Biolabs is answering the call with the AI-driven antibody discovery platform, an out-of-the-box system that combines machine learning with decades of proprietary data to predict high-potential candidates in record time.
Dive into Creative Biolabs' Tech-Powered Pipeline
1.AI-Powered Candidate Screening
The journey starts with Creative Biolabs' AI-driven lead discovery, where algorithms analyze billions of data points to identify antibodies with optimal binding affinity and stability, reducing the candidate pool from thousands to a focused shortlist, saving months of trial and error.
2.Validation & Optimization
Top candidates undergo rigorous lab testing, including surface plasmon resonance (SPR) and ELISA assays, to confirm functionality. Utilizing techniques like HPLC and mass spectrometry, Creative Biolabs' antibody purification & characterization services ensure industry-grade quality.
3.Customization & Scalability
For IF, FC, and IHC assays, cell imaging, and protein or antigen detection, the company supplies antibody labeling kits to realize rapid conjugation with fluorescent dyes, biotin, or enzymes with precision at a microscopic level. Clients can then scale production under GMP guidelines, supported by end-to-end regulatory guidance.
